{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:44Z","timestamp":1793467604508,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00277-017-3082-y","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T08:47:33Z","timestamp":1501922853000},"page":"1653-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire N.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Flindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Boothroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Spierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Perez Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Taylor-Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"key":"3082_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. doi: 10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"3082_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. doi: 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"3082_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"RA Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study, 1976-1995. Am J Hematol 61:10\u201315","journal-title":"Am J Hematol"},{"key":"3082_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2796.2004.01357.x","volume":"256","author":"P Johansson","year":"2004","unstructured":"Johansson P, Kutti J, Andr\u00e9asson B, Safai-Kutti S, Vil\u00e9n L, Wedel H, Ridell B (2004) Trends in the incidence of chronic Philadelphia chromosome negative (Ph\u2212) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 256:161\u2013165. doi: 10.1111\/j.1365-2796.2004.01357.x","journal-title":"J Intern Med"},{"key":"3082_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 89:581\u2013587","journal-title":"Am J Hematol"},{"key":"3082_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.2830470205","volume":"47","author":"BJ Ania","year":"1994","unstructured":"Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd (1994) Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 47:89\u201393","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"3082_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijlh.12509","volume":"38","author":"JT Geyer","year":"2016","unstructured":"Geyer JT, Orazi A (2016) Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic\/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol 38(Suppl 1):12\u201319. doi: 10.1111\/ijlh.12509","journal-title":"Int J Lab Hematol"},{"key":"3082_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ebiom.2016.01.010","volume":"3","author":"JB Kaplan","year":"2016","unstructured":"Kaplan JB, Stein BL, McMahon B, Giles FJ, Platanias LC (2016) Evolving therapeutic strategies for the classic Philadelphia-negative myeloproliferative neoplasms. EBioMedicine 3:17\u201325. doi: 10.1016\/j.ebiom.2016.01.010","journal-title":"EBioMedicine"},{"key":"3082_CR9","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","volume":"124","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Mesa RA (2014) Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 124:3529\u20133537. doi: 10.1182\/blood-2014-05-577635","journal-title":"Blood"},{"key":"3082_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2011.92","volume":"25","author":"A Tefferi","year":"2011","unstructured":"Tefferi A (2011) Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia 25:1059\u20131063. doi: 10.1038\/leu.2011.92","journal-title":"Leukemia"},{"key":"3082_CR11","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. doi: 10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"3082_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. doi: 10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"key":"3082_CR13","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. doi: 10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"3082_CR14","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T et al (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108:3472\u20133476. doi: 10.1182\/blood-2006-04-018879","journal-title":"Blood"},{"key":"3082_CR15","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30:4098\u20134103. doi: 10.1200\/JCO.2012.42.3863","journal-title":"J Clin Oncol"},{"key":"3082_CR16","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC et al (2014) Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:3803\u20133810. doi: 10.1182\/blood-2013-09-527903","journal-title":"Blood"},{"key":"3082_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18. doi: 10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"key":"3082_CR18","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the international working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20132901. doi: 10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"key":"3082_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703\u20131708. doi: 10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"key":"3082_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397. doi: 10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"key":"3082_CR21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874\u20131881. doi: 10.1038\/leu.2013.163","journal-title":"Leukemia"},{"key":"3082_CR22","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:3179\u20133184. doi: 10.1200\/JCO.2010.34.5298","journal-title":"J Clin Oncol"},{"key":"3082_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M et al (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167. doi: 10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"key":"3082_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68\u201376. doi: 10.1002\/cncr.22365","journal-title":"Cancer"},{"key":"3082_CR25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","volume":"54","author":"J Abelsson","year":"2013","unstructured":"Abelsson J, Andr\u00e9asson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P (2013) Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma 54:2226\u20132230. doi: 10.3109\/10428194.2013.766732","journal-title":"Leuk Lymphoma"},{"key":"3082_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/10428194.2011.619608","volume":"53","author":"P Johansson","year":"2012","unstructured":"Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgeg\u00e5rd G, Andr\u00e9asson B (2012) Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma 53:441\u2013444. doi: 10.3109\/10428194.2011.619608","journal-title":"Leuk Lymphoma"},{"key":"3082_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P et al (2011) The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118:401\u2013408. doi: 10.1182\/blood-2011-01-328955","journal-title":"Blood"},{"key":"3082_CR28","first-page":"E1345","volume":"101","author":"R Scherber","year":"2016","unstructured":"Scherber R, Dueck A, Geyer H et al (2016) Symptoms, risk classification, and spleen size in JAK2 inhibitor-na\u00efve myelofibrosis: implications for JAK2 inhibitor treatment. Haematologica 101:E1345","journal-title":"Haematologica"},{"key":"3082_CR29","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V128.22.3117.3117","volume":"128","author":"RM Scherber","year":"2016","unstructured":"Scherber RM, Geyer H, Dueck AC et al (2016) Symptom burden as primary driver for therapy in patients with myelofibrosis: an analysis by MPN International Quality of Life Study Group [abstract]. Blood 128:3117","journal-title":"Blood"},{"key":"3082_CR30","unstructured":"National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines. Myeloproliferative neoplasms V2.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf . Accessed November 11, 2016"},{"issue":"Suppl 5","key":"3082_CR31","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, Guidelines Committee ESMO (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v85\u2013v99. doi: 10.1093\/annonc\/mdv203","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3082-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T04:26:57Z","timestamp":1602649617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3082-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3082-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,5]]}}}